Cookson Peirce & Co. Inc. Acquires New Shares in Adaptive Biotechnologies Corporation $ADPT

Cookson Peirce & Co. Inc. purchased a new stake in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 40,449 shares of the company’s stock, valued at approximately $868,000.

A number of other large investors have also made changes to their positions in the company. 1492 Capital Management LLC bought a new stake in Adaptive Biotechnologies during the 4th quarter worth approximately $1,484,000. Jupiter Asset Management Ltd. lifted its position in Adaptive Biotechnologies by 33.8% in the 4th quarter. Jupiter Asset Management Ltd. now owns 362,811 shares of the company’s stock valued at $5,892,000 after acquiring an additional 91,683 shares in the last quarter. Westfield Capital Management Co. LP acquired a new position in Adaptive Biotechnologies in the 4th quarter worth $65,942,000. Rhenman & Partners Asset Management AB boosted its stake in Adaptive Biotechnologies by 22.2% in the 4th quarter. Rhenman & Partners Asset Management AB now owns 605,000 shares of the company’s stock worth $9,825,000 after purchasing an additional 110,000 shares during the period. Finally, Wasatch Advisors LP bought a new position in Adaptive Biotechnologies during the 2nd quarter worth about $12,361,000. Institutional investors own 99.17% of the company’s stock.

Adaptive Biotechnologies Stock Performance

NASDAQ ADPT opened at $25.19 on Monday. Adaptive Biotechnologies Corporation has a 12 month low of $12.00 and a 12 month high of $26.87. The company has a current ratio of 4.79, a quick ratio of 4.68 and a debt-to-equity ratio of 2.22. The stock has a 50 day moving average of $22.92 and a 200-day moving average of $17.66. The company has a market cap of $4.02 billion, a PE ratio of -61.44 and a beta of 2.08.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its earnings results on Wednesday, July 29th. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.12). The firm had revenue of $71.55 million for the quarter, compared to analyst estimates of $65.44 million. Adaptive Biotechnologies had a negative return on equity of 36.81% and a negative net margin of 20.73%.Adaptive Biotechnologies’s quarterly revenue was up 21.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.17) earnings per share. On average, equities research analysts anticipate that Adaptive Biotechnologies Corporation will post -0.4 EPS for the current fiscal year.

Insider Activity

In other Adaptive Biotechnologies news, insider Sharon Benzeno sold 154,768 shares of the company’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $21.14, for a total value of $3,271,795.52. Following the sale, the insider owned 221,278 shares in the company, valued at $4,677,816.92. This represents a 41.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter M. Neupert sold 124,690 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $25.15, for a total value of $3,135,953.50. Following the completion of the sale, the director directly owned 130,625 shares of the company’s stock, valued at approximately $3,285,218.75. The trade was a 48.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 2,062,325 shares of company stock valued at $46,659,069. 5.70% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. Morgan Stanley lifted their price target on Adaptive Biotechnologies from $20.00 to $22.00 and gave the company an “equal weight” rating in a research note on Thursday, July 30th. Guggenheim upped their price objective on Adaptive Biotechnologies from $22.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. TD Cowen increased their price objective on Adaptive Biotechnologies from $25.00 to $28.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. JPMorgan Chase & Co. dropped their target price on Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 6th. Finally, BTIG Research boosted their target price on Adaptive Biotechnologies from $24.00 to $25.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $24.42.

Adaptive Biotechnologies Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.